By G HossainPosted on January 16, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is underway, with data expected this quarter. Speculation of Sanofi Takeover Sends Ocular’s Stock Soaring Post navigation JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the RearviewJPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer